Work

Correlation of Serum Levels of Endostatin with Tumor Stage in Gastric Cancer: A Systematic Review and Meta-Analysis

Year: 2015

Type: review

Study designs: Systematic Review, Meta-Analysis

Abstract: BACKGROUND: We performed a systematic review and meta-analysis to study the association between serum endostatin levels and gastric cancer (GC) progression. METHOD: We searched the MEDLINE, Science Citation Index, Cochrane Library, PubMed, Embase, Current Contents Index, and several Chinese databases for published studies relevant to our study topic. Carefully selected studies were pooled and SMD and its corresponding 95% CI were calculated. Version 12.0 STATA software was used for statistical analysis. RESULTS: Serum endostatin levels were analyzed in 12 case-control studies (736 GC patients and 350 controls). Significant differences in serum endostatin levels were observed between GC patients and the healthy controls (SMD = 1.418, 95% CI = 1.079~1.757, P < 0.001). Importantly, significantly lower levels of serum endostatin were found in I-II grade patients compared to those with III-IV grade tumors (P < 0.001). Further, higher serum endostatin levels were observed in the LN invasion-positive GC subjects in comparison with LN invasion-negative subjects (P < 0.001). CONCLUSION: Patients with GC exhibited elevated levels of serum endostatin than controls and its level showed a statistical correlation with the more aggressive type of GC, exhibiting invasion and LN metastasis. Thus, serum levels of endostatin being a useful prognostic biomarker for GC patients warrants further investigation.

Source: BioMed Research International

DOI: 10.1155/2015/623939

Authors: Zheng-Hua Wang, Zhi-Tu Zhu, Xu-Yang Xiao, Jin Sun

Institution: First Affiliated Hospital of Liaoning Medical University

Language: English

Topic: Gastric Cancer Management and Outcomes

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $2,680